Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Protease inhibitor BI-201335 potent in clinical studies in hepatitis C

Jan. 11, 2010

Results reported from first-in-human trial of hepatitis C therapeutic ABT-072

Jan. 11, 2010

Hepatitis C therapeutic filibuvir safe and well tolerated in phase I-II studies

Jan. 11, 2010

INCB-7839 improves response to trastuzumab in metastatic HER2+ breast cancer

Jan. 7, 2010

8-Chloro-adenosine to be investigated in patients with breast cancer

Jan. 5, 2010

Data reported from three phase II studies of BIBW-2992 in metastatic breast cancer

Jan. 5, 2010

Millennium's TAK-285 may have potential to treat brain metastases from breast cancer

Jan. 4, 2010

IGF-I receptor inhibitor PQIP enhances doxorubicin cytotoxicity in human cancer cell lines

Jan. 4, 2010

Recommended phase I dose of breast cancer candidate SR-16157 determined

Jan. 4, 2010

Preclinical studies reveal potential of KX-01 for treatment of breast cancer

Jan. 4, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 28, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...